Belzutifan Combo Could be Second-Line Option in Advanced RCC

by admin | Mar 2, 2026 | Health

Spread the love

Belzutifan plus lenvatinib significantly improves outcomes vs single agent cabozantinib in patients with advanced RCC who progressed after anti-PD-(L)1 therapy, new data show.
Medscape Medical News

← Oil, gasoline prices jump amid Iran strikes, with future uncertain Commentary: Japanese investment in China keeps rising despite political tensions →

Written By

Written by Albert Pham, News Curator and Blogger

AI Startup Red Queen Bio Uses Artificial Intelligence to Prepare for a Future Pandemic

Sep 28, 2026 | albertpham, Economy_finances, Health, Technology

Red Queen Bio is using AI to design antibody drugs against novel pathogens, highlighting the growing role of artificial intelligence in pandemic preparedness and biotech.

Harvard, MIT Professors Move to Canada Amid U.S. Research Funding Cuts

Sep 25, 2026 | albertpham, Economy_finances, Health, Politics

Harvard and MIT professors are moving to Canadian universities as Canada invests billions to attract global researchers amid U.S. research funding uncertainty.

Americans Could Lose Access to Cheaper Canadian Prescription Drugs

Sep 22, 2026 | albertpham, Economy_finances, Health

U.S. customs changes could restrict Americans’ access to cheaper prescription drugs from Canada and other foreign pharmacies starting in October.

Belzutifan Combo Could be Second-Line Option in Advanced RCC

Written By

Related Posts

AI Startup Red Queen Bio Uses Artificial Intelligence to Prepare for a Future Pandemic

Harvard, MIT Professors Move to Canada Amid U.S. Research Funding Cuts

Americans Could Lose Access to Cheaper Canadian Prescription Drugs

0 Comments

Explore More

Connect With Us

Quick Links

Legal

Stay Updated